Deputy Chief Pharmacist and Governance and Clinical Lead at The Queen Elizabeth Hospital King's Lynn NHS Foundation Trust
Primum non nocereSubscription
We welcome the comments from Stuart Hill providing a counter-argument to the concerns initially raised by the UK Clinical Pharmacy Association Respiratory Group about Relvar Ellipta.
Our concerns with Relvar ElliptaSubscription
We would like to alert pharmacists to the potential for inadvertent dosing errors that may occur when patients are prescribed the new Relvar Ellipta (fluticasone furoate/vilanterol) inhaler for asthma or chronic obstructive pulmonary disease. Pharmacists should be alert to the fact that the licensed strengths of Relvar Ellipta (92µg/22µg and 184µg/22µg) are equivalent to medium to high doses of fluticasone propionate (500µg and 1,000µg, respectively). There is no low-dose inhaled corti